TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

This treatment has been approved for sale to the public.

Study NCT00245739 Information provided by Tibotec Pharmaceuticals, Ireland

First Received: October 27, 2005 Last Updated: February 7, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This treatment has been approved for sale to the public.
Study Completion Date:	September 2009
Primary Completion Date:	September 2009 (Final data collection date for primary outcome measure)